Hana Biosciences, Inc. - Product Pipeline Review - Q4 2010

Hana Biosciences, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Hana Biosciences, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Hana Biosciences, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hana Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hana Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hana Biosciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Hana Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Hana Biosciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Hana Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Hana Biosciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Hana Biosciences, Inc. and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Hana Biosciences, Inc. Snapshot
Hana Biosciences, Inc. Overview
Key Information
Key Facts
Hana Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Hana Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Hana Biosciences, Inc. – Pipeline Products Glance
Hana Biosciences, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Hana Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Hana Biosciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Hana Biosciences, Inc. – Drug Profiles
Marqibo
Product Description
Mechanism of Action
R&D Progress
Marqibo
Product Description
Mechanism of Action
R&D Progress
Vincristine Sulfate + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Alocrest
Product Description
Mechanism of Action
R&D Progress
Brakiva
Product Description
Mechanism of Action
R&D Progress
Menadione topical lotion
Product Description
Mechanism of Action
R&D Progress
Marqibo
Product Description
Mechanism of Action
R&D Progress
Hana Biosciences, Inc. – Pipeline Analysis
Hana Biosciences, Inc. – Pipeline Products by Therapeutic Class
Hana Biosciences, Inc. Pipeline Products By Target
Hana Biosciences, Inc. – Pipeline Products by Route of Administration
Hana Biosciences, Inc. – Pipeline Products by Molecule Type
Hana Biosciences, Inc. – Recent Pipeline Updates
Hana Biosciences, Inc. – Company Statement
Hana Biosciences, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 29, 2010: Hana Biosciences To Present Data On Marqibo At ASH Annual Meeting
Jul 08, 2010: Hana Biosciences Receives US Patent For Menadione For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash
Jun 07, 2010: Hana Biosciences Reports Data From Pivotal Phase II Trial Of Marqibo In Advanced Relapsed/Refractory Adult Ph(-) Acute Lymphoblastic Leukemia
Mar 30, 2010: Hana Receives Notice Of Allowance For Menadione Patent For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash
Mar 30, 2010: Hana Receives Notice Of Allowance For Menadione Patent For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash
Mar 03, 2010: Hana Biosciences Announces New Positive Interim Efficacy Results In Pivotal rALLy Clinical Trial Of Marqibo In Acute Lymphoblastic Leukemia
Dec 07, 2009: Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial Of Marqibo in Acute Lymphoblastic Leukemia At 51st American Society Of Hematology Annual Meeting
Sep 30, 2009: Hana Biosciences Enters Into Clinical Trial Agreement With The National Cancer Institute For Development Of Marqibo In Pediatric Cancer
Jun 02, 2009: Hana Biosciences Presents Updated Marqibo Data At The American Society Of Clinical Oncology Annual Meeting
Financial Deals Landscape
Hana Biosciences, Inc., Deals Volume Summary, 2004 to YTD 2010
Hana Biosciences, Inc., Deals Summary By Region, 2004 to YTD 2010
Hana Biosciences, Inc., Deals Summary, 2004 to YTD 2010
Hana Biosciences, Inc. Detailed Deal Summary
Asset Purchase
Hana Biosciences Acquires Laboratory Equipment From Inex Pharmaceuticals
Private Equity
Hana Biosciences Completes Private Equity Financing Of $4.7 Million
Equity Offering
Hana Biosciences Completes Private Placement Of $12.4 Million
Hana Biosciences Completes Private Placement Of $5 Million
Hana Biosciences Completes Private Placement Of $40 Million
Hana Biosciences Completes Private Placement Of $10 Million
Hana Biosciences Completes Private Placement $14.8 Million
Hana Biosciences Completes Common Stock Offering Of $4.93 Million
NovaDel Completes Private Placement Of $1 Million
Hana Biosciences Completes Private Placement Of $0.5 Million
Hana Biosciences Completes Private Placement Of $8 Million
Hana Biosciences Enters Into Agreement With Center for Cancer Research
Licensing Agreements
Hana Biosciences Enters Into Licensing Agreement With Albert Einstein College For Menadione
Hana Biosciences Enters Into Licensing Agreement With Inex Pharmaceuticals
Hana Biosciences Enters Into License Agreement With Novadel Pharma
Hana Biosciences Enters Into Licensing Agreement With Yale University And The Research Foundation Of The State University Of New York
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer